亚太药业(002370) - 2025 Q2 - 季度业绩预告

Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. 2025 Semi-Annual Performance Forecast Item I. Current Period Performance Forecast The company forecasts a significant increase in net profit attributable to shareholders for H1 2025, reaching 100-110 million RMB, while non-recurring adjusted net profit is expected to be a loss of 44-54 million RMB, and operating revenue is projected to decline to 150-155 million RMB - The performance forecast period is from January 1, 2025, to June 30, 2025[2] 2025 Semi-Annual Performance Forecast | Item | Current Period Forecast | Prior Period | Year-over-Year Change | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Shareholders | Profit: 100 million–110 million RMB | Profit: 5.4752 million RMB | Growth: 1726.42% - 1909.06% | | Net Profit Excluding Non-Recurring Items | Loss: 44 million–54 million RMB | Loss: 7.8267 million RMB | Decline: 462.18% - 589.95% | | Operating Revenue | 150 million–155 million RMB | 221.9333 million RMB | Approx. Decline: 30.25%-32.41% | | Basic Earnings Per Share | Profit: 0.1357-0.1492 RMB/share | Profit: 0.01 RMB/share | Approx. Growth: 1257%-1392% | Item II. Communication with Accounting Firms The financial data disclosed in this performance forecast has not been audited by a certified public accountant - The financial data related to this performance forecast has not been audited by a certified public accountant[3] Item III. Explanation of Performance Changes The significant increase in net profit is primarily due to non-recurring gains from the sale of a subsidiary, while the decline in non-recurring adjusted net profit is attributed to reduced sales from centralized procurement and market competition, alongside increased financial expenses from convertible bond redemption - The significant increase in net profit attributable to shareholders (1726.42% - 1909.06%) is mainly due to the company's sale of 100% equity in its wholly-owned subsidiary, Shaoxing Xingya Pharmaceutical Co., Ltd., which increased the total profit for H1 2025 (non-recurring gain) by approximately 149 million RMB[4][5] - The decline in net profit excluding non-recurring items (462.18%-589.95%) is primarily due to: - Sales revenue decreased to some extent during the reporting period due to factors such as centralized procurement and intensified market competition[5] - The company's convertible bonds matured on April 2, 2025, and all un-converted bonds (remaining 2,472,253 shares) were redeemed at 115% of their par value, leading to an increase in financial expenses[5] Item IV. Other Related Information This performance forecast represents preliminary estimates by the company's finance department, is unaudited, and investors are advised to consider investment risks as final data will be in the 2025 semi-annual report - This performance forecast is a preliminary estimate by the company's finance department and has not been audited by an accounting firm[6] - Specific financial data will be subject to the disclosures in the 2025 semi-annual report[6] - Investors are advised to make prudent decisions and be aware of investment risks[6]